ResMed Q2 FY2024 revenue $1.16B (+12% YoY); non-GAAP EPS $1.88 (+13%)

RESMED INC

2024-Q2 EPS reported $2.90 revenue$2,265,122,000

Revenue $1,162.8M (+12% YoY, +11% constant currency); GAAP op profit down 2%, non-GAAP op profit up 20% to $365.5M.
GAAP diluted EPS $1.42 (-7%); non-GAAP diluted EPS $1.88 (+13%), driven by revenue growth and cost discipline.
Board declared $0.48/share quarterly cash dividend with record date Feb 8, payable March 14.
Resumed share repurchase program; repurchased $50M of common stock during the quarter.
Gross margin contracted 50 bps to 55.6% GAAP; non-GAAP gross margin improved 10 bps to 56.9%.

item 2.02 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

RESMED INC reported quarter ended December 31, 2023 results: revenue $1,162.8, net income $208.8, EPS $1.42.

Period: quarter ended December 31, 2023
Revenue: $1,162.8
Net income: $208.8
EPS: $1.42
Result: reported results

Exact text from the filing

and Operating Metrics Unaudited; $ in millions, except for per share amounts Three Months Ended December 31, 2023 December 31, 2022 % Change Constant Currency (A) Revenue $ 1,162.8 $ 1,033.7 12 % 11 % Gross margin 55.6 % 56.1 % (1 ) Non-GAAP gross margin (B) 56.9 % 56.8 % — Selling, general, and administrative expenses 222.2 211.7 5 4 Research and

View on SEC.gov

Browse all earnings releases →

RESMED INC filing history →

Source: SEC EDGAR

accession 0001193125-24-014223

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.